NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer

Table 1

Clinical characteristics of patients included in the study.

	All patients (n = 39)		pCR (n = 8) (20.5%)		Non-pCR (n = 31) (71.5%)
Age at diagnosis (years)	48	26 to 63	47	38 to 57	48	26 to 63	0.73
BMI (body mass index, kg/m^2)	28.20	20.80 to 39.70	28.4	20.80 to 39.70	28.20	24.80 to 33.10	0.88
<25	8	20.51%	1	12.50%	7	22.58%
>25	28	71.80%	6	75.00%	22	70.97%
No data	3	7.69%	1	12.50%	2	6.45%
Menopause status
Pre	21	53.85%	5	62.50%	16	51.61%	0.88
Post	18	46.15%	3	37.50%	15	48.39%
Family history
Yes	19	48.72%	3	37.50%	16	51.61%	0.75
No	20	51.28%	5	62.50%	15	48.39%
Diabetes mellitus
Yes	2	5.13%	0	0.00%	2	6.45%	0.87
No	37	94.87%	8	100.00%	29	93.55%
Number of children			3.6		3.2		0.44
Nulliparous	4	10.26%	0	0.00%	4	12.90%	0.22
1 or 2	12	30.77%	2	25.00%	10	32.26%
>3	23	58.97%	6	75.00%	17	54.84%
Lactation
Yes	16	41.03%	3	37.50%	13	41.94%	0.97
No	11	28.20%	2	25.00%	9	29.03%
No data	12	30.77%	3	37.50%	9	29.03%
Smoking
Yes	5	12.82%	2	25.0%	3	9.68%	0.25
No	34	87.18%	6	75.0%	28	90.32%
Clinical stage
I	1	2.56%	1	12.50%	0	0.00%	0.82
II	19	48.72%	2	25.00%	17	54.84%
III	19	48.72%	5	62.50%	14	45.16%
TNM classification
T1	1	2.56%	1	12.50%	0	0.00%	0.93
T2	18	46.15%	1	12.50%	17	54.84%
T3	11	28.21%	4	50.00%	7	22.58%
T4	9	23.08%	2	25.00%	7	22.58%
N0	7	17.95%	2	25.00%	5	16.13%
N1	23	58.97%	4	50.00%	19	61.29%
N2	9	23.08%	2	25.00%	7	22.58%
M0	39	100.00%	8	100.0%	31	100.00%
IHC markers
ER+	16	41.03%	2	25.00%	14	45.16%	0.30
ER-	23	58.97%	6	75.00%	17	54.84%
PR +	17	43.59%	2	25.00%	15	48.39%	0.23
PR-	22	56.41%	6	75.00%	16	51.61%
HER2+	7	17.95%	5	62.50%	2	6.45%	0.002
HER2 -	32	82.05%	3	37.50%	29	93.55%
ki67	15.40	5 to 70	17.14	5 to 50	14.92	2 to 70	0.76
Molecular subtype
Luminal A	10	25.64%	1	12.50%	9	29.03%	0.51
Luminal B	6	15.39%	0	0.00%	6	19.36%
HER2+	7	17.95%	5	62.50%	2	6.45%
Triple-negative	16	41.02%	2	25.00%	14	45.16%
NUSAP1 (BS)^a
Overexpressed	17	43.59%	2	25.00%	15	48.39%	0.43
Underexpressed	22	56.41%	6	75.00%	16	51.61%
PCLAF (BS)^a
Overexpressed	18	46.15%	4	50.00%	14	45.16%	>0.99
Underexpressed	21	53.85%	4	50.00%	17	54.84%
NUSAP1 (SS)^a
Overexpressed	12	30.77%	0	0.00%	12	38.71%	0.04
Underexpressed	27	69.23%	8	100.00%	19	61.29%
PCLAF (SS)^a
Overexpressed	28	71.80%	1	12.50%	29	93.55%	0.0001
Underexpressed	11	28.20%	7	87.50%	2	6.45%

a NUSAP1 or PCLAF were identified as overexpressed or underexpressed based on the contrast pCR vs. non-pCR in BS or SS samples as specified.